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A versatile platform for
autologous bone growth in vivoDental implants are the current solution for replacement of missing teeth.
However, the majority of patients with implants suffer from implant diseases
caused by microbial infection and bone loss. There is an unmet need for the
treatment of dental diseases. We developed a safe, cheap, and fast applicable
glue with antimicrobial properties, designed for the treatment of periodontal
diseases. This material can be delivered in liquid form around the implant and
solidified by using a dental light to prevent infection and promote bone healing.Shirzaei Sani et al., Matter 1, 926–944
October 2, 2019 ª 2019 Elsevier Inc.
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ArticleAn Antimicrobial Dental Light
Curable Bioadhesive Hydrogel
for Treatment of Peri-Implant Diseases
Ehsan Shirzaei Sani,1 Roberto Portillo Lara,2 Zahra Aldawood,3 Seyed Hossein Bassir,3,4
Daniel Nguyen,5 Alpdogan Kantarci,5 Giuseppe Intini,6,7,8 and Nasim Annabi1,9,10,11,*Progress and Potential
Clinical management of peri-
implant diseases (PIDs)
constitutes significant challenges.
Here, we report a multi-functional
adhesive hydrogel with
antimicrobial properties for
treatment of PIDs. The hydrogel
precursor can be crosslinked in
seconds using commercially
available dental curing systems
and forms a hydrogel that can
adhere to both soft tissues
(gingiva) and hard tissues (dental
implants/bone). The hydrogel wasSUMMARY
Dental implants remain the standard of care to replace missing teeth, which has
led to an increase in the number of patients affected by peri-implant diseases
(PIDs). Here, we report the development of an antimicrobial bioadhesive, Ge-
lAMP, for the treatment of PIDs. The hydrogel is based on a visible-light-acti-
vated naturally derived polymer (gelatin) and an antimicrobial peptide (AMP).
The optimized formulation of GelAMP could be rapidly crosslinked using com-
mercial dental curing systems. When compared with commercial adhesives,
GelAMP exhibited significantly higher adhesion to physiological tissues and
titanium surfaces. Moreover, the bioadhesive showed high cytocompatibility
and could efficiently promote cell proliferation and migration in vitro. GelAMP
also showed remarkable antimicrobial activity against Porphyromonas gingiva-
lis. Furthermore, it could support the growth of autologous bone after sealing
calvarial bone defects in mice. Overall, GelAMP could be used as a platform
for the development of more effective therapies against PIDs.extensively characterized in vitro,
ex vivo, and in vivo. The






hydrogel adhesive could be used
as a minimally invasive platform
for the development of more
effective therapeutic strategies
against PIDs.INTRODUCTION
As dental implants have become the standard of care for the replacement of missing
teeth, the number of patients affected by peri-implant diseases (PIDs) is increasing.1
According to their clinical manifestations, PIDs can be mainly categorized in peri-
implant mucositis (PIM) and peri-implantitis (PI).2 PIM refers to a reversible inflamma-
tory process that affects the soft tissues surrounding an implant, resulting in
bleeding on gentle probing and, in some cases, suppuration, erythema, and
swelling.2 The etiology of PIM is the bacterial accumulation and biofilm formation
around the dental implant.3 On the other hand, PI presents not only with inflamma-
tion of the soft tissues but is also accompanied by a progressive bone loss that could
lead to implant failure.4 Clinical data have shown that progression from PIM to PI is
strongly associated with lack of preventive maintenance; thus, opportune treatment
of PIM could prevent the progression to PI.5
Currently, PIM can be treated with nonsurgical procedures, which include mechan-
ical debridement, alone or in combination with local delivery of antibiotics such as
Arestin (minocycline HCl), Elyzol (metronidazole 25%), and Atridox (doxycycline hy-
clate 10%), which can be injected directly into the sulcus or peri-implant pockets.6,7
However, because of their inability to efficiently antagonize the infection,8 the ther-
apeutic efficacy of these approaches is limited.9 In addition, local and systemic
administration of antibiotics may result in hypersensitivity reactions in allergic pa-
tients, as well as the development of antibiotic-resistant strains of pathogenic926 Matter 1, 926–944, October 2, 2019 ª 2019 Elsevier Inc.
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https://doi.org/10.1016/j.matt.2019.07.019bacteria.10,11 Moreover, as the number of dental implants being placed has
continued to increase worldwide; it is predicted that PIDs will become one of the
most prominent dental diseases of the future.3 Therefore, there is a need for more
effective therapeutic strategies that could be used to prevent bacterial growth
and promote healing around dental implants for the treatment of PIDs.
Current treatments against PIM are mainly aimed at eradicating subgingival dysbiosis
and restoring homeostasis to microbial communities in the oral cavity.12 However, clin-
ical data have shown that nonsurgical mechanical approaches, aimed at disinfection of
the affected area, often fail due to recolonization of the periodontal or peri-implant
pockets by pathogenic bacteria that perpetuate the disease.12,13 Moreover, bacterial
infection and the subsequent epithelial cell death lead to the release of inflammatory cy-
tokines and chemotactic bacterial peptides, which attract migratory neutrophils. This
can worsen implant prognosis, mainly because neutrophil degranulation due to bacte-
rial overload releases tissue-degrading enzymes into the gingival crevice that lead to
further tissue trauma.14,15 As inflammation extends from the marginal gingiva into the
supporting periodontal tissues, PIM could eventually progress to PI and lead to bone
loss and implant failure. Therefore, therapeutic strategies that efficiently isolate the
affected area to prevent the infiltration of bacteria and other unwanted cells, while
also enabling the growth of bone-competent cells (i.e., compartmentalized tissue heal-
ing), could improve the clinical outcome of patients with PIDs.16,17
Periodontal regeneration requires the hierarchical and coordinated response of a
variety of soft and hard tissues (i.e., periodontal ligament, gingiva, cementum,
and bone) during the wound-healing process.18 In recent years, clinical evidence
has shown that treatment options based on resorbable and non-resorbable mem-
branes could be used for guided tissue regeneration of the periodontal tissues
affected by PIDs.19 Current third-generation membranes are developed not only
to act as passive barriers but also as delivery vehicles for the release of specific an-
tibiotics and growth factors.20,21 Moreover, local delivery yields higher local concen-
trations of the therapeutic agents, which increases the effectiveness at the site and
decreases the risk of systemic side effects. However, several limitations remain per-
taining to the unpredictability of the efficacy of these treatments and the need for
the delivery of multiple biological mediators to promote tissue regeneration.22,23
Hydrogel-based bioadhesives hold remarkable potential for soft- and hard-tissue
engineering applications due to their tunable composition and physical properties.
The precise control over the microarchitecture, mechanical properties, and degra-
dation rate of hydrogels make them useful alternatives for the controlled delivery
of a variety of therapeutic agents in vivo. For instance, our group has previously re-
ported the development of antimicrobial hydrogel adhesives for the treatment of
chronic nonhealing wounds24 and orthopedic applications,25 which were based on
extracellular matrix (ECM)-derived biopolymers. In the field of regenerative
dentistry, previous studies have reported the engineering of hydrogels based on
the combination of alginate with the soluble and insoluble fractions of the dentin ma-
trix.26 More recently, other groups have developed cell-laden gelatin-based hydro-
gels that could be photopolymerized using dental curing lights.27 However, to the
best of our knowledge, the development of antimicrobial hydrogels that can
strongly adhere to hard and soft oral surfaces for the treatment of PIDs has not
been reported.
Here, we describe the development of a visible-light crosslinkable antimicrobial hy-
drogel adhesive for the treatment of PIDs. This bioadhesive was engineered throughMatter 1, 926–944, October 2, 2019 927
the incorporation of a cationic antimicrobial peptide (AMP) (Tet213) into a photo-
crosslinkable gelatin methacryloyl hydrogels to form gelatin methacryloyl-antimicro-
bial peptide (GelAMP) bioadhesives. We characterized the physical and adhesive
properties of the bioadhesives in vitro. We also evaluated the antimicrobial proper-
ties of the bioadhesives against Porphyromonas gingivalis, a Gram-negative bacte-
rium that is involved in the pathogenesis of PIDs. The cytocompatibility of GelAMP
was also evaluated in vitro via two-dimensional (2D) surface seeding and three-
dimensional (3D) encapsulation of W-20-17 murine fibroblasts. Lastly, we evaluated
the ability of the bioadhesives to support bone regeneration in vivo using a calvarial
defect model in mice. The engineered antimicrobial bioadhesives could constitute
an effective approach to prevent bacterial growth while also supporting tissue
regeneration for the treatment of PIDs.RESULTS AND DISCUSSION
Synthesis and Physical Characterization of the Bioadhesive Hydrogels
The GelAMP bioadhesives were synthesized based on the combination of biocom-
patible photoinitiators (triethanolamine [TEA]/N-vinyl caprolactam [VC]/Eosin Y), a
naturally derived gelatin-based biopolymer (gelatin methacryloyl), and an AMP
(Tet213). Type I or cleavage-type initiators are widely used in tissue engineering
and are designed to be activated within the range of UV wavelength (i.e.,
360–400 nm). However, exposure to UV light could lead to cell damage,28 impair
cellular function,29 and even lead to neoplasia and cancer.30 Moreover, only a few
type I photoinitiators such as 2-hydroxy-40-(2-hydroxyethoxy)-2-methylpropiophe-
none (Irgacure-2959) and lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP)
have been shown to be cytocompatible at low concentrations.30–32 Irgacure-2959
has low water solubility and cannot be activated with visible light since its molar ab-
sorptivity is limited in the visible-light range (wavelengths >400 nm). Although LAP
has high water solubility and cytocompatibility, its highest molar absorbance is in
UV-range wavelengths (365–385 nm, ez 150–230 M1 cm1), which limits its activa-
tion in the visible-light range (ez 30 M1 cm1 at 405 nm).33 Considering the effec-
tive wavelength of Food and Drug Administration (FDA)-approved dental curing
light systems (420–480 nm), cleavage-type photoinitiators have limited potential
to be used with these platforms in the clinical setting. To address these limitations,
we used a visible-light-activated photoinitiator, Eosin Y, which is known as type II or
noncleavage-type photoinitiator. This photoinitiator not only can minimize the
safety concerns associated with UV light, but also can be rapidly activated with wave-
lengths (420–480 nm, e > 50,000 M1 cm1) produced by commercial dental curing
systems.33,34 TEA and VC were used as a co-initiator and a co-monomer respec-
tively, to assist free radical photoinitiation.34
Hydrogels were synthesized using the highly cytocompatible and visible-light-acti-
vated polymer gelatin methacryloyl, a chemically modified form of hydrolyzed
collagen that possesses a high number of cell-binding motifs and matrix-metallopro-
teinase (MMP) degradation sites.31 These characteristics are critical to ensure proper
cell attachment and colonization of the scaffold. Lastly, we incorporated AMP Tet213
into the bioadhesive precursor to impart antimicrobial properties to the hydrogels.
AMPs do not readily lead to the selection of resistant mutants and are effective at
very low concentrations, which makes them ideal candidates to prevent bacterial
growth in biomedical implants via local delivery.35 To form the antimicrobial GelAMP
bioadhesives, we dissolved the gelatin methacryloyl prepolymer at various concen-
trations (7% and 15%) in a photoinitiator solution containing Tet213 (0.2% [w/v], or
1.34 mM) and photocrosslinked using a dental curing light (420–480 nm) (Figure 1A).928 Matter 1, 926–944, October 2, 2019
Figure 1. Physical Characterization of the Bioadhesive Hydrogels
(A) Synthesis and photocrosslinking process of the bioadhesive hydrogels.
(B–D) Elastic and compressive modulus (B), extensibility (C), and ultimate stress (D) of the adhesive hydrogels produced by using 7% and 15% (w/v) total
polymer concentration with and without AMP.
(E and F) In vitro degradation properties in 20 mg/mL collagenase type II solution in Dulbecco’s phosphate-buffered saline (DPBS) (E) and swelling ratios
in DPBS for 7% and 15% (w/v) adhesive hydrogels with and without AMP (F).
Data are presented as mean G SD (**p < 0.01, ***p < 0.001, ****p < 0.0001; n R 5).Control hydrogels (Gel) were formed using a similar technique, but without incorpo-
ration of AMP.
To evaluate the physical properties of the bioadhesives, we synthesized hydrogel
formulations based on two different concentrations of bioadhesive (7% and 15%
[w/v]) with and without incorporation of AMP. Our results showed that 15% (w/v)Matter 1, 926–944, October 2, 2019 929
bioadhesive hydrogels exhibited a 4.3-fold and 3.2-fold increase in the compressive
and elastic moduli, respectively, when compared with 7% (w/v) hydrogels (Fig-
ure 1B). In addition, the extensibility of the bioadhesives did not change by changing
the concentration of bioadhesive from 7% to 15% (w/v) or by the addition of AMP
(Figure 1C). However, the ultimate tensile strength of hydrogels increased from
5.2 G 1.3 kPa to 19.8 G 3.5 kPa as the bioadhesive concentration was increased
from 7% to 15% (w/v) (Figure 1D). The results also showed that the addition of
AMP did not alter the mechanical properties of the bioadhesives, which could be
due to the low concentration and the small size of the AMP.24
Next, we examined the in vitro stability of the bioadhesives by incubating them in
collagenase type II solution in Dulbecco’s phosphate-buffered saline (DPBS)
(20 mg/mL) for 5 days. Bioadhesives with 7% (w/v) concentration resulted in signifi-
cantly accelerated degradation as compared with bioadhesives with 15% (w/v) con-
centration. In particular, the 7% (w/v) bioadhesive showed 100.0% degradation at
day 5 post incubation, while only 29.4%G 2.2% of the hydrogel with 15% (w/v) con-
centration was degraded during the same time (Figure 1E). In addition, there was no
significant difference in the degradation of bioadhesive hydrogels with or without
AMP (Figure 1E).
The in vivo biodegradation of GelAMP bioadhesive was also confirmed in a rat
subcutaneous implantation model. Accordingly, hematoxylin and eosin (H&E) anal-
ysis of the explanted samples revealed a significant deformation and biodegrada-
tion of hydrogels after 56 days of implantation when compared with day 7 (Fig-
ure S4). This can be mainly due to the enzymatic hydrolysis of the gelatin
backbone.25
We then determined the water uptake capacity of the hydrogels by calculating the
swelling ratios of the bioadhesives at different concentrations and time points. For
this, the swelled weights of the samples after incubation at 37C in DPBS were
divided by their corresponding dry weights. As shown in Figure 1F, the swelling
ratios of the hydrogels decreased by increasing bioadhesive concentrations. How-
ever, the swelling ratios barely changed after 10 h of incubation, indicating that the
equilibrium states were achieved at this time point. In addition, the incorporation
of AMP did not alter the degradation rate and the swellability of the bioadhesives
(Figures 1E and 1F). Overall, bioadhesives with 15% (w/v) concentration
showed higher mechanical stiffness and slower degradation rates compared with
7% (w/v) hydrogels. Previous studies have also investigated the effects of physical
properties and microstructural features of hydrogel scaffolds on the regeneration
and repair of target tissues.24,36 An ideal bioadhesive used in the setting of the
oral cavity should be elastic and flexible, as well as sufficiently strong to withstand
breakage due to the intrinsic dynamism of the oral tissues.37 For this purpose, the
water uptake capacity of the bioadhesives should be finely tuned to prevent exces-
sive swelling, which could lead to patient discomfort and detachment from the wet
and highly motile oral tissues. Furthermore, fast degradation of the adhesive could
compromise adequate retention and greatly limit their clinical efficacy.24 Our re-
sults showed that, in addition to the higher modulus (Figure 1B) and ultimate
strength (Figure 1D) of the 15% (w/v) bioadhesives, they also showed compara-
tively higher structural stability in vitro. This was demonstrated by their slower
degradation rates (Figure 1E) and similar swelling equilibrium states upon incuba-
tion in DPBS (Figure 1F) when compared with 7% (w/v) bioadhesives. Next, we
evaluated the adhesive properties of the hydrogels to soft physiological tissues
and hard implant surfaces.930 Matter 1, 926–944, October 2, 2019
Figure 2. In Vitro and Ex Vivo Adhesion Properties of the Bioadhesive Hydrogels
(A and B) Representative images of (A) wound closure test using pig gingiva tissue based on ASTM
standard test (F2458-05) and (B) adhesion strength of the bioadhesive hydrogels and a
commercially available adhesive (CoSEAL) to porcine gingiva.
(C) Schematic of the in vitro lap shear test based on a modified ASTM standard (F2255-05), using
titanium as a substrate.
(D) The in vitro lap shear strength of the bioadhesive hydrogels at 7% and 15% polymer
concentration and a commercially available adhesive (CoSEAL).
Data are presented as mean G SD (ns, not significant; ***p < 0.001, ****p < 0.0001; n R 5).In Vitro and Ex Vivo Characterization of the Adhesive Properties
The strong retention and adhesion of biomaterials to both the native tissue and the
implant surface is a critical factor in promoting periodontal tissue repair and regen-
eration.38 Moreover, the designed bioadhesive must withstand the shear and the
pressure exerted by the underlying tissues and the high motility of the oral tissues.
To evaluate these parameters, we performed standard in vitro adhesion tests
including wound closure (ASTM F2458-05), lap shear (ASTM F2255-05), and burst
pressure (ASTM F2392-04) to assess the adhesiveness of the hydrogels to physio-
logical tissues and titanium surfaces. Similar tests were also performed using a
commercially available sealant, CoSEAL, as control. Wound closure tests were per-
formed to measure the adhesive strength of the bioadhesives to soft tissues
including porcine gingiva (Figures 2A and 2B) and porcine skin (Figure S1). The
results of the wound closure tests revealed that the adhesive strength of the hydro-
gel to gingiva increased from 23.5 G 5.4 kPa to 55.3 G 6.7 kPa, by increasing the
hydrogel concentration from 7% to 15% (w/v) (Figure 2B). Similarly, the adhesive
strength of the bioadhesives to porcine skin was increased 2.1-fold by increasing
the total polymer concentration from 7% to 15% (w/v) (Figure S1). Moreover, the
presence of AMP did not alter the adhesion strength of the hydrogels for both
porcine gingiva and skin tissues (Figures 2B and S1). Lastly, the adhesive strength
of the 15% (w/v) bioadhesive was significantly higher than that of CoSEAL, with a
3.3-fold difference for gingiva tissue and a 1.7-fold difference for skin tissue (Fig-
ures 2B and S1).
Similar to the wound closure tests, 15% (w/v) bioadhesives, with and without AMP,
showed significantly higher lap shear strength to titanium surface as comparedMatter 1, 926–944, October 2, 2019 931
with CoSEAL (i.e., 3.7- and 4.6-fold difference, respectively) (Figure 2D). However,
the lap shear strength did not significantly change for 15% (w/v) bioadhesives with
and without AMP (Figure 2D). In contrast, the burst pressure of the bioadhesives
was increased from 17.0 G 2.9 kPa at 7% (w/v) to 34.6 G 4.0 kPa at 15% (w/v) final
polymer concentration. Furthermore, the highest burst pressure was observed for
15% (w/v) hydrogels (37.7 G 6.5 kPa), which was significantly higher than that of
CoSEAL (1.7 G 0.1 kPa) (Figure S2).
Different hydrogel adhesives have been used for sealing, reconnecting tissues, or as
implant coatings.38,39 However, their poor mechanical properties and adhesion to
wet tissues have limited their implementation in the clinic. Moreover, the majority
of the commercially available dental adhesives are based on polymethyl methacry-
late- or acrylic-based resins, which are mainly used as fillers for dentin cavities.
Although these types of adhesives have shown strong adhesion and binding to
the oral surfaces and tissues (i.e., gingiva and pulpal walls), their potential as a plat-
form for the treatment of PIDs is limited.40,41 This is mainly due to the lack of cell-
binding sites and poor tissue biointegration, which ultimately limit the regenerative
capacity of these resins.41 In contrast, our results revealed that our visible-light
curable bioadhesives are able to bind strongly to both hard (titanium) and soft
(gingiva tissue) surfaces and withstand high shear stress and pressure. In addition,
we have previously shown that gelatin-based bioadhesives can strongly adhere to
wet and dynamic tissues such as the lung.31 Therefore, these bioadhesives could
be used to effectively adhere to periodontal tissues, as well as under palatal pressure
and during mastication. Moreover, due to the high regenerative capacity of ECM-
derived biopolymers, gelatin-based bioadhesives could constitute a suitable alter-
native for the treatment of PIDs.24
In Vitro Evaluation of the Antimicrobial Properties of the Bioadhesives
AMPs are composed of short sequences of cationic amino acids, which have been
shown to possess broad-spectrum bactericidal activity against both normal and anti-
biotic-resistant bacteria.24,35 AMPs bind to the negatively charged outer leaflet of
bacterial cell membranes, which leads to changes in bacterial surface electrostatics,
increased membrane permeabilization, and cell lysis.24
Here, we synthesized GelAMP, a dental light curable bioadhesive with antimicro-
bial properties through the incorporation of AMP into bioadhesive hydrogels. Pre-
viously, we have shown that AMP Tet213 at very low concentrations is effective
against both Gel (+/) bacteria.24 Here, we used an optimized concentration of
AMP in this work (0.2% [w/v]) based on our previous study.24 First, we evaluated
the antimicrobial activity of the resulting bioadhesive against P. gingivalis using
a standard colony-forming units (CFU) assay and direct visualization of the bacte-
ria-laden hydrogels via scanning electron microscopy (SEM) (Figure 3). The CFU
assay showed that the number of P. gingivalis colonies in the 3-logarithmic dilution
decreased from 37.7 G 3.5 at 0.0% (w/v) AMP to 10.6 G 1.9 at 0.2% (w/v) AMP
(Figures 3A and 3B). A similar response was also observed for the 4-logarithmic
dilution, which further confirmed the bactericidal properties of the engineered
antimicrobial GelAMP bioadhesives when compared with pristine hydrogels as
control (Figure 3B). SEM micrographs also showed that the hydrogels without
AMP exhibited significant bacterial infiltration and colonization throughout the
polymer network (Figure 3C). In contrast, GelAMP containing 0.2% (w/v) AMP
showed high antimicrobial activity as demonstrated by the complete absence of
bacterial clusters on both surface and cross-sections of the bioadhesives
(Figure 3D).932 Matter 1, 926–944, October 2, 2019
Figure 3. In Vitro Antibacterial Properties of the Bioadhesive Hydrogels against P. gingivalis
(A) Representative images of P. gingivalis colonies grown on blood agar plates for bioadhesives
with and without AMP (Dilution 1, 3 and 4 represent 1-, 3-, and 4-logarithmic dilutions, respectively).
(B–D) Quantification of colony-forming units (CFU) for bioadhesive hydrogels with and without AMP
(0.2% [w/v] or 1.34 mM), seeded with P. gingivalis bacteria (day 4) (B). Representative SEM images of
P. gingivalis colonization on bioadhesive hydrogels containing (C) 0% and (D) 0.2% (w/v) AMP.
Clusters of bacteria are indicated by yellow arrows (scale bars: 1 and 2 mm).
***p < 0.001, ****p < 0.0001.A variety of AMPs such as defensins and cathelicidins are normally found in the oral
cavity, particularly in the gingival crevicular fluid and in salivary secretions, and
constitute the first line of defense against bacterial infection.42 Moreover, AMPs
do not trigger resistance mechanisms, and play a key role in the regulation of micro-
bial homeostasis and the progression of gingival and periodontal diseases.43
Because of this, previous groups have explored the use of AMPs as active coatings
for dental implants and other therapeutic strategies aimed at the prevention of bac-
terial infection.44,45 However, AMPs are highly susceptible to proteolytic degrada-
tion by proteases secreted by bacteria and host cells and, thus, efficient in vivo de-
livery of AMPs to the site of infection remains challenging. Thus, the engineered
bioadhesives in this work could be used to protect AMPs from environmental degra-
dation and to deliver physiologically relevant concentrations of AMPs for controlled
periods of time.Cell Studies
An ideal bioadhesive not onlymust be cytocompatible but should also allow the attach-
ment and proliferation of cells within the 3D microstructure to support biointegration
and healing. Here, we assessed the ability of the engineered bioadhesives to support
the attachment and proliferation of migratory cells from the bone stroma via 3D encap-
sulation of bone marrow stromal cells (Figure 4). In addition, we evaluated the ability of
the bioadhesives to support the growth and proliferation of migratory stromal cells via
3D encapsulation of freshly isolated calvarial bone sutures.
In Vitro Cytocompatibility and Proliferation of 3D Encapsulated Cells within the
Bioadhesive Hydrogels
First, we evaluated the viability, metabolic activity, and spreading of bone
marrow mouse stromal cells (W-20-1746) encapsulated within the adhesives usingMatter 1, 926–944, October 2, 2019 933
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Figure 4. In Vitro 3D Encapsulation of W-20-17 Cells and Mouse Calvarial Bone Sutures inside the Bioadhesive Hydrogels
(A) Representative live/dead images of W-20-17 cells encapsulated within bioadhesive hydrogels with and without AMP after 1 and 5 days (scale bar:
200 mm).
(B) Quantification of viability of W-20-17 cells incorporated within hydrogels without (control) and with AMP (GelAMP) using live/dead assays on days 1,
3, and 5 post encapsulation.
(C) Representative phalloidin (green)/DAPI (blue)-stained images of cell-laden bioadhesives with and without AMP after 1 and 5 days (scale bar: 200 mm).
(D) Quantification of metabolic activity of W-20-17 cells encapsulated in hydrogels after 1, 3, and 5 days.
(E) Schematic diagram of the extraction and encapsulation of mouse calvarial bone sutures in 3D hydrogel network.
(F) Representative images of calvarial bone sutures encapsulated within 7% and 15% (w/v) bioadhesives to visualize growth and diffusion of cells on days
10, 20, and 30 post-encapsulation.
(G) Quantification of metabolic activity of migratory stromal cells from encapsulated bone sutures. Bioadhesive hydrogels were formed at 120 s visible
light exposure time.
ns, not significant;*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.live/dead and PrestoBlue assays, and F-actin/DAPI staining, respectively. Our results
showed that cells encapsulated within the bioadhesives with and without AMP ex-
hibited >90% viability after 5 days of culture (Figures 4A and 4B). In addition, the
incorporation of AMP did not affect the viability of the encapsulated cells (Figures
4A and 4B). Moreover, F-actin/DAPI staining revealed that W-20-17 cells could atta-
ch and proliferate throughout the 3D network for both Gel and GelAMP adhesives
up to 5 days of culture (Figure 4C). Furthermore, the metabolic activity of cells in
GelAMP hydrogels increased consistently from 2,273 G 66 relative fluorescence
units (RFU) at day 1 to 10,041G 938 RFU at day 5 of culture (Figure 4D). In addition,
there were no statistically significant differences between the metabolic activity of
cells seeded on GelAMP and Gel adhesives (Figure 4D).
3D Encapsulation of Calvarial Bone Suture Explants within the Bioadhesives
We encapsulated the freshly isolated calvarial bone sutures in both 7% and 15% (w/v)
hydrogels to evaluate the ability of the bioadhesives to support the proliferation and
migration of stromal cells (Figure 4E). During the first week of encapsulation, no
significant cell migration was observed. A week after encapsulation, cell (most likely
suture-derived skeletal stem cells47,48) deployment out of the suture was observed,
followed by proliferation and migration within the bioadhesive hydrogel (Figure 4F).
The migratory and proliferative behavior of these cells was assessed for up to
30 days post-encapsulation (Figure 4F). The results showed that the metabolic
activity of the encapsulated cells increased consistently for both 7% and 15% (w/v)
bioadhesives (Figure 4G). For instance, the metabolic activity of the cells in 15%
GelAMP (w/v) bioadhesives increased from 3,016 G 678 RFU at day 10 to
22,869 G 3,421 RFU at day 30 post encapsulation (Figure 4G). However, we did
not observe any statistical difference between metabolic activity of the cells seeded
within the 7% and 15% (w/v) bioadhesive hydrogels (Figure 4G).
Our results also indicated that the GelAMP bioadhesives did not elicit any cytotoxic
response and could effectively support the growth of both W-20-17 and suture-
derived skeletal stem cells in vitro. Previous studies have reported the development
of different types of antimicrobial hydrogels based on the incorporation of metal or
metal oxide nanoparticles.24,49 However, the negative effect of metal oxide nano-
particles on cell viability greatly limits their application for the clinical management
of PIDs.49 In contrast, our results demonstrated that the cells could infiltrate and
spread throughout GelAMP bioadhesives while also remaining proliferative and
metabolically active.
Taken together, these results demonstrated that our bioadhesives could be used to
form an adhesive and antimicrobial barrier that prevents bacterial growth and sup-
ports the proliferation of bone-competent cells in vitro. The ability of GelAMPMatter 1, 926–944, October 2, 2019 935
bioadhesives to eradicate or prevent infection at the implant site could not only be
relevant to disinfect the affected area, but also to reduce inflammatory responses
triggered by sustained microbial colonization. Moreover, the establishment of a
cell-supportive microenvironment could promote the regeneration of the affected
bone by endogenous progenitor cells that migrate into the wound site. Therefore,
we next aimed to evaluate the ability of the bioadhesives to support bone regener-
ation in vivo using a calvarial defect model in mice.
In Vivo Application and Evaluation of the Bioadhesive Hydrogels
We investigated the ability of the bioadhesives to be delivered and formed in situ
and to remain firmly attached to the wound area without the risk of displacement
during the healing process. For this, we first created critically sized defects in
mice calvaria using dental drills. The bioadhesive precursor solutions (7% and 15%
[w/v]) were directly injected into the bone defects and photopolymerized using a
commercial dental light curing unit (Figure 5A). Our results showed that the bio-
adhesives could remain at the site of application without any sign of displacement
after 7 and 14 days of implantation (Figure 5B). In addition, histological assessment
(using H&E) showed the complete sealing of the defect and a strong coherence be-
tween the bioadhesive and the native bone following application (Figure 5C).
Moreover, the H&E images also revealed that bioadhesives with both formulations
(7% and 15% [w/v]) could remain attached to the wound site up to 42 days after
application (Figures 5D and 5E). At earlier time points (14 days post application),
the formation of new autologous bone could be observed near the margin of the
original defect (Figure S3). Calvarial defects in untreated control animals showed
limited new bone formation at day 42 post application (Figure 5F). In contrast, his-
tological staining revealed the formation of new bone for both 7% and 15% (w/v) bio-
adhesives (Figures 5D and 5E). Furthermore, the area covered by the newly formed
bone was significantly larger for defects treated with 15% (w/v) hydrogels compared
with 7% (w/v) hydrogels (Figure S3). This observation could be explained in part due
to the increased structural integrity of bioadhesives with higher polymer concentra-
tion, which provided a more structurally stable scaffold to support bone regenera-
tion and the ingrowth of the adjacent connective tissues (Figure 5E). These observa-
tions provided qualitative evidence that was indicative of the formation of new bone
and the subsequent repair of the defect.
To perform a quantitative evaluation of new bone formation, we performed micro-
computed tomography (mCT) on untreated defects as well as defects treated with
bioadhesives synthesized using 7% and 15% (w/v) polymer concentrations at days
0, 28, and 42 post procedure (Figure 6). Our results showed that the untreated de-
fects exhibited limited evidence of bone formation up to 28 and 42 days post pro-
cedure, with little decrease in the extension of the critical size (Figure 6A). At day
28, the defects treated with the 15% (w/v) hydrogels showed significantly higher
bone formation than 7% (w/v) hydrogels and the untreated groups. At day 42, a sig-
nificant amount of new bone was observed for defects treated with 15% (w/v) hydro-
gels (Figure 6A). In addition, on days 28 and 42, the bone surface area (BS) and the
bone volume (BV) for 15% (w/v) hydrogels were shown to be significantly higher than
that of untreated and 7% (w/v) groups (Figures 6B and 6C). For instance, at day 42,
the BS for 15% (w/v) hydrogels corresponded to 2.96 G 0.46 mm2, which was
significantly higher than those of the untreated controls (i.e., 1.03 G 0.63 mm2)
and 7% (w/v) hydrogels (i.e., 1.40 G 0.53 mm2) (Figure 6B). Moreover, the highest
BV was observed for 15% (w/v) bioadhesives (i.e., 7.16 G 1.65 mm3), which was
significantly higher than those of untreated (i.e., 2.76G 1.03 mm3) and 7% (w/v) bio-
adhesives (i.e., 4.45G 0.72 mm3) (Figure 6C). Statistical analysis indicated that both936 Matter 1, 926–944, October 2, 2019
Figure 5. In Vivo Evaluation of the Bioadhesive Hydrogels Using a Mouse Calvarial Defect Model
(A) Schematic diagram of in situ application of bioadhesive hydrogels in a mouse calvarial defect
model.
(B) Bioadhesive hydrogels (7% and 15%) were delivered to artificially created bone defects in mouse
calvaria (yellow arrowheads), and photopolymerized for 1 min using a commercially available
dental curing light. Seven and 14 days after implantation, samples remained in place, without any
sign of detachment.
(C–F) Histological evaluation (H&E staining) of the 15% (w/v) bioadhesives at day 0 post
implantation (C). Representative H&E images for (D) 7% (w/v) and (E) 15% (w/v) bioadhesive
treatments, and (F) untreated sample after 42 days of implantation (scale bars: 1 mm and 50 mm).the concentration of the biopolymer and the treatment time had a significant effect
on BV and BS. For instance, the BS and BV increased 1.27- and 1.66-fold, respec-
tively, at 28 and 42 days post procedure, which was indicative of sustained bone
regeneration throughout the experiment (Figures 6B and 6C).
The higher degree of bone regeneration observed for 15% (w/v) bioadhesive could be
due in part to the direct contribution of the enhanced mechanical properties of hydro-
gels with higher polymer concentrations.36 For instance, Huebsch et al. demonstrated
that the contributionofmatrix elasticity to newbone formation in vivo is highly correlated
with mechanically induced osteogenesis.36 They reported that the BV and mineral den-
sity obtained for hydrogels with elasticities in the range of 60 kPa was significantly higher
than those with 5-kPa or 120-kPa moduli.36 In our study, 15% (w/v) bioadhesives, which
exhibited elastic and compressive modulus corresponding to 53.0 G 10.3 kPa and
52.2G 4.7 kPa (Figure 1B), respectively, could potentially enable mechanically inducedMatter 1, 926–944, October 2, 2019 937
Figure 6. Quantitative Evaluation of New Bone Formation Using mCT Analysis
(A) Representative mCT images for untreated defect, and defects treated with 7% and 15%
bioadhesives on days 28 and 42 post implantation.
(B and C) Quantitative analysis of bone surface area (B) and bone volume (C). Data are presented as
mean G SD (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; n = 5).osteogenesis and thus promote the formation of new bone in vivo. However, the clinical
efficacy of antimicrobial bioadhesives for the treatment of patients with advanced PI
could be limited due to the lack of a bona fide osteoinductive strategy. Although previ-
ous groups have reported the development of regenerative bioadhesives, they often
rely on the use of growth factors,50,51 stem cells,36,52 and other bioactive molecules.53,54
These methods often suffer from clinical limitations and drawbacks.55,56 Due to these
limitations, in our future work we will introduce a cell-/growth factor-free strategy by
the incorporation of alternative osteoinductive strategies such as nanosilicates57 into
antimicrobial bioadhesives, which could constitute an attractive platform for the devel-
opment of osteoinductive and antimicrobial bioadhesives for the treatment of PIDs.
Conclusion
The clinical management of PIDs still constitutes significant challenges for clinicians
and researchers in the dentistry field. In this study, we engineered antimicrobial hy-
drogel bioadhesives for the treatment of PIDs. The hydrogel precursors could be
readily delivered and photocrosslinked in situ using commercial dental curing sys-
tems. These bioadhesives exhibited tunable mechanical stiffness and elasticity,
and comparatively higher adhesive strength to implant and oral surfaces than com-
mercial adhesives. In addition, the bioadhesives showed high antimicrobial activity
in vitro against P. gingivalis, a pathogenic bacterium associated with the onset and
progression of PIDs. In vitro and ex vivo studies demonstrated that the bioadhesives
were highly cytocompatible and could provide a suitable microenvironment for
migratory stromal cells deployed from encapsulated bone sutures. Furthermore,
in vivo studies showed that the bioadhesives could promote bone regeneration938 Matter 1, 926–944, October 2, 2019
by supporting the growth of migratory progenitor cells. Taken together, our results
demonstrated the remarkable potential of our bioadhesive hydrogels to be used as
adhesive, antimicrobial, and cell-supportive barriers that can support tissue healing
and bone regeneration in vivo for the treatment of PIDs.EXPERIMENTAL PROCEDURES
Synthesis of Photocrosslinkable Bioadhesive Prepolymers
Gelatin methacryloyl was synthesized as previously described.58–60 In brief, 10 g of
gelatin from cold water fish skin (Sigma-Aldrich) was dissolved in 100 mL of DPBS at
60C for 30 min. Next, 8% (v/v) methacrylic anhydride (Sigma-Aldrich) was added to
the solution dropwise under vigorous stirring at 60C for another 3 h. The solution
was then diluted with 300 mL of DPBS to stop the reaction and dialyzed (Spectrum
Laboratories, molecular weight cutoff = 12–14 kDa) in a deionized water bath at
50C for 5 days to remove the unreacted methacrylic anhydride. The resulting solu-
tion was filtered and lyophilized for 4 days.Fabrication of Bioadhesive Hydrogels
Adhesive hydrogels (Gel) were formed by first dissolving different concentrations of
gelatin methacryloyl (7% and 15% [w/v]) in the photoinitiator solution containing
TEA (1.88% [w/v]) and VC (1.25% [w/v]) in distilled water at room temperature. A
separate solution of Eosin Y disodium salt (0.5 mM) was also prepared in distilled
water. The biopolymer/TEA/VC solutions were then mixed with Eosin Y prior to
crosslinking to form the final precursor solution. To form the hydrogels, we
pipetted 70 mL of the precursor solution into polydimethylsiloxane (PDMS) cylindri-
cal molds (diameter: 6 mm; height: 2.5 mm) for compressive tests, or rectangular
molds (12 3 5 3 1 mm) for tensile tests. Lastly, the solutions were photocrosslinked
upon exposure to visible light (420–480 nm) for 120 s, using a VALO dental light
curing unit (Ultradent Products). GelAMP hydrogels were formed by dissolving
0.2% (w/v) AMP Tet213 (CSC Scientific) in TEA/VC/Eosin Y photoinitiator solution.
The lyophilized biopolymers were then dissolved in the resulting solution and photo-
crosslinked as described above.Mechanical Properties
The tensile and compressive properties of the hydrogel adhesives were evaluated
using an Instron 5542 mechanical tester, as described previously25 (Supplemental
Experimental Procedures).In Vitro Swellability and Degradation
The in vitro swellability (24 h) and degradation (14 days) of bioadhesives were per-
formed in DPBS as described previously25 (Supplemental Experimental Procedures).In Vitro Adhesion
In Vitro Wound Closure
Wound closure test was performed on both porcine gingiva and skin tissues using a
modified ASTM F2458-05 test, as described previously.25 In brief, the porcine
gingiva was isolated from fresh porcine mandible. Tissues were then cut into 1 3
2-cm pieces and kept moist prior to the test. The tissues were glued onto two precut
glass slides (20 3 30 mm), then 50 mL of precursor solution was pipetted and cross-
linked using a dental light curing system to form the adhesives. The samples were
then placed between the Instron tensile grips and the ultimate adhesive strength
was calculated at break (nR 5). Similarly, 50 mL of the commercial adhesive material
was tested as a control.Matter 1, 926–944, October 2, 2019 939
In Vitro Lap Shear
The lap shear strength of the bioadhesives and a commercial adhesive, CoSEAL
(Baxter, Deerfield, IL, USA), was determined according to a modified ASTM test
(F2255-05). Both titanium and glass slides were used as the substrates. Glass slides
(103 30mm) were coated with gelatin solution and dried at 37C. For adhesive tests
on titanium, a piece of titanium (103 10 mm) was attached to a glass slide and 10 mL
of the precursor solution was photocrosslinked between the titanium and the
gelatin-coated glass slide. The lap shear strength of the adhesives was then
measured under tensile stress at a rate of 1 mm/min using an Instron mechanical
tester. The ultimate stress was reported as shear strength of the bioadhesives
(nR 5). Similarly, 10 mL of the commercial adhesive material was tested as a control.
In Vitro Burst Pressure
The burst pressures of the bioadhesives and CoSEAL were determined using amodi-
fied ASTM (F2392-04) test as described previously.24 A piece of porcine intestine
was fixed between the stainless-steel annuli of a custom-designed burst pressure
setup. A 2-mm defect was then created on the center of the tissue. Next, 30 mL pre-
cursor solution was applied to the defect site and crosslinked using a dental light
curing system. Air pressure was then applied to the sealed tissue and the maximum
resistance pressure was recorded as burst pressure (n R 5). Similarly, 30 mL of the
commercial adhesive material was tested as a control.
In Vitro Antimicrobial Properties of Adhesive Hydrogels
P. gingivalis (clinical isolate A743661) was used to evaluate the antimicrobial
properties of GelAMP bioadhesives. P. gingivalis was grown on 5% sheep’s
blood agar plates supplemented with hemin and vitamin K (H & K) in an anaer-
obic system (5% H2, 15% CO2, 80% N2) at 37C for 7 days. The bacteria colonies
were then transferred to Wilkins-Chalgren Anaerobe Broth (Oxoid) medium to
prepare a 108 CFU/mL bacterial solution. For antimicrobial tests, 1 mL of a 108
CFU/mL bacteria solution was seeded on cylindrical hydrogels with and without
AMP (0% and 0.2% [w/v] or 1.34 mM) in 24-well plates. After 72 h of anaerobic
incubation, the samples were removed from the medium and washed gently
three times with DPBS. Next, each sample was placed in 1 mL of DPBS and vor-
texed for 15 min to release bacteria from within the scaffold. The solutions were
then logarithmically diluted to 101, 103, and 104 dilutions. A 30-mL volume of
each dilution was then seeded on sheep’s blood agar plates with H & K and incu-
bated for 5 days. The number of colonies was counted and reported for each
sample (n = 4). For SEM imaging, hydrogels were removed from the medium
and washed three times with DPBS. The samples were then fixed in a solution
of 2.5% (v/v) glutaraldehyde (Sigma-Aldrich) and 4% (v/v) paraformaldehyde
(Sigma-Aldrich) in DPBS for 30 min. After fixation, the samples were gently
washed three times with DPBS and dehydrated using a serially diluted ethanol
solution in water (30%, 50%, 70%, 90%, and 100% [v/v]). The samples were
then dried using a critical point dryer. Lastly, the samples were mounted on
aluminum SEM stubs, sputter coated with 6 nm of gold/palladium, and imaged
by a Hitachi S-4800 scanning electron microscope (n = 3).
In Vitro Cell Studies
Cell Lines
Bone marrow mouse stromal cells (W-20-17) were cultured at 37C and 5% CO2 in
Minimum Essential Medium (MEM) Alpha medium without ascorbic acid (Gibco),
containing 10% (v/v) fetal bovine serum (FBS) and 1% (v/v) penicillin/streptomycin
(Gibco).940 Matter 1, 926–944, October 2, 2019
2D Cell Seeding on Adhesive Hydrogels
Hydrogels were formed by pipetting 10 mL of precursor solution between a 3-(trime-
thoxysilyl) propyl methacrylate (TMSPMA; Sigma-Aldrich)-coated glass slide
(103 10 mm) and a glass coverslip separated with a 100-mm spacer. Bioadhesive hy-
drogels were photocrosslinked using visible light for 60 s. The hydrogels were
seeded with W-20-17 cells (53 106 cells/mL) and kept at 37C, 5% CO2 for 5 days.
60
3D Cell Encapsulation within the Engineered Hydrogels
For 3D cell encapsulation, a suspension of W-20-17 cells (5 3 106 cells/mL) was pre-
pared by trypsinization and resuspension in MEM alpha medium. The cell suspension
was centrifuged to form a cell pellet and themediumwas discarded. A hydrogel precur-
sor containing 7% bioadhesive was prepared in culture medium containing TEA/VC/
Eosin Y and mixed with the cell pellet. Hydrogels were formed by pipetting 10 mL of
the precursor solution between a TMSPMA-coated glass slide and a glass coverslip
separated with a 100-mm spacer, and photocrosslinking upon exposure to visible light
for 60 s. Lastly, the glass slides with the encapsulated W-20-17 cells were placed in
24-well plates and incubated in MEM alpha at 37C and 5% CO2.
Cell Viability, Proliferation, and Spreading
A calcein AM/ethidium homodimer-1 live/dead kit (Invitrogen) was used to evaluate
cell viability as described previously.62 Cell proliferation and metabolic activity was
determined using a commercial PrestoBlue assay (Fisher) on days 0, 1, 3, and 5 as
described previously.25 Cell spreading in 2D and 3D cultures was evaluated via fluo-
rescent staining of F-actin microfilaments and cell nuclei25,63 (Supplemental Exper-
imental Procedures) (nR 3).Animal Studies
Calvarial Bone Suture Tissue Extraction and Encapsulation into the Gels
All animal experiments were performed according to the Guide for the Care and Use
of Laboratory Animals (IACUC approval IS00000535) at Harvard School of Dental
Medicine. For all experiments, 7- to 8-week-old wild-type house mice (Mus muscu-
lus) were used. To obtain the calvarial bone sutures, we first euthanized the mice by
CO2 inhalation, before carrying out cervical dislocation. After decapitation, the head
was cleaned using 70% ethanol. A cut was then created through the skin at the base
of the skull using a surgical blade. Next, an incision was made starting at the nose
bridge and ending at the base of the skull followed by removal of the skin from
the top of the head. The calvaria was then cut and transferred to a Petri dish with
DPBS. After washing with DPBS, the soft tissues were removed using tweezers and
the sutures were isolated using scissors. The isolated tissues were chopped into
small fragments of 1–2 mm2 and quickly transferred to ice-cold cell culture medium
prior to use. For encapsulation, the suture fragments were placed on a flat Petri dish,
in between two spacers (500 mm). Next, 70 mL of the bioadhesive precursor was pi-
petted on the tissue samples and covered by a glass coverslip. The samples were
then photocrosslinked for 2 min using a dental curing light. Samples were removed
from Petri dishes and placed in 12-well tissue culture plates. Next, 2 mL of MEM
Alpha medium, containing 10% (v/v) FBS and 1% (v/v) penicillin/streptomycin, was
added to each well and the samples were incubated at 37C for up to 30 days.
The samples were imaged using a Zeiss Primo Vert inverted microscope, and the
cell metabolic activity was evaluated as described previously (nR 3).
Mouse Calvarial Bone Defect Model
Male and female mice were assigned randomly to all experimental groups. After
general anesthesia, 2-mm round defects were made with a surgical bur on rightMatter 1, 926–944, October 2, 2019 941
and left parietal bone of mice. Next, 10 mL of the precursor solution was injected in
the defect sites (7% and 15% [w/v]) and photopolymerized using a dental light curing
unit for 1 min. After anatomical wound closure, the animals recovered from anes-
thesia. At each time point, the animals were euthanized by CO2 inhalation, followed
by cervical dislocation. After euthanasia, calvarial tissues were collected for mCT and
histological analysis (Supplemental Experimental Procedures) (nR 3).
Statistical Analysis
All data are presented as mean G standard deviation (*p < 0.05, **p < 0.01,
***p < 0.001, and ****p < 0.0001). T test, one-way ANOVA, or two-way ANOVA fol-
lowed by Tukey’s test were performed using the GraphPad Prism 6.0 Software.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.matt.
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